Makers Laboratories Limited share price
Makers Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations in India. It operates in two segments, Pharmaceutical and Chemical Manufacturing. The company offers general health therapeutic products, including acid regulatory, anthelmintic, anti-allergic, anti-asthmatic, anti-biotic, anti-diabetics, anti-diarrhoeals, anti-emetics and anti-nauseants, anti-fungal, anti-hypertensive, antiinflammatory, analgesic, anti-spasmodic, anti-malarial, and anti-thyroid. It also provides cough and cold control, digestives, neurotonics, nutritional supplements, topical anti-biotic/anti-microbial, and other specialty drugs. The company sells its products under th…Read more
- Market Cap₹ 123 Cr.
- Current Price₹ 208.11
- High / Low₹ 236 / 150
- Stock P/E35.9
- Book Value₹ 124
- Dividend Yield0.00 %
- ROCE9.0 %
- ROE3.30 %
- Face Value—
More figures (10)
- EPS (TTM)₹ 5.79
- Price / Book1.68
- OPM7.5 %
- Debt / Equity0.08
- Sales growth (4Y)11.4 %
- Profit growth (4Y)—
- Promoter holding67.5 %
- EV / EBITDA9.1
- Beta0.22
- All-time high₹ 236
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| MAKERSL | +16.97% | — | — | — | — | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Makers Laboratories Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹123 crore.
- It trades at 35.9 times its last 12 months' earnings and 1.7 times book value.
- Revenue grew 11.4% a year over the last 4 years.
- Return on equity was 3.3% and return on capital employed 9.0% in the latest year.
- Debt was 0.08 times shareholders' equity.
- The share price is 11.8% below its 52-week high.
- Promoters and insiders hold about 67.5%; institutions about 0.0%.
Pros
AI- Company is almost debt-free (debt is 0.08 times equity).
Cons
AI- Return on equity has been low: 1.7% on average over the last 3 years.
- The company has not paid a dividend recently.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Makers Laboratories Limited
Makers Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations in India. It operates in two segments, Pharmaceutical and Chemical Manufacturing. The company offers general health therapeutic products, including acid regulatory, anthelmintic, anti-allergic, anti-asthmatic, anti-biotic, anti-diabetics, anti-diarrhoeals, anti-emetics and anti-nauseants, anti-fungal, anti-hypertensive, antiinflammatory, analgesic, anti-spasmodic, anti-malarial, and anti-thyroid. It also provides cough and cold control, digestives, neurotonics, nutritional supplements, topical anti-biotic/anti-microbial, and other specialty drugs. The company sells its products under the Duramol, Artemak-AB, Loroquin, Nimuwin, Coffwin, and Exylin brands. It distributes its products through agents, stockiest, doctors, and retailers. The company also exports its products. Makers Labor…
- Employees
- 114
- Head office
- Mumbai
Peer comparison
HealthcareDrug Manufacturers - Specialty & Generic
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Makers Laboratories | 208.11 | 35.9 | 123 | 0.00 | 2 | 244.47 | 43 | 22.20 | 9.0 | 3.3 | 1.68 | 7.5 | 0.08 | 67.54 | 140 | 11.4 |
| 2. | Sun Pharmaceutical Industries | 1,758.80 | 34.9 | 4,21,995 | 0.91 | 2,895 | 34.65 | 15,184 | 18.48 | 17.9 | 14.7 | 5.05 | 23.4 | 0.06 | 55.61 | 58,220 | 10.4 |
| 3. | Divi's Laboratories | 9,144.50 | 83.0 | 2,42,758 | 0.33 | 902 | 36.25 | 3,080 | 19.15 | 19.0 | 16.2 | 14.48 | 28.4 | 0.00 | 52.00 | 10,476 | 11.0 |
| 4. | Torrent Pharmaceuticals | 4,558.90 | 72.8 | 1,73,406 | 0.83 | 566 | 3.28 | 4,921 | 54.85 | 9.1 | 27.1 | 18.39 | 25.0 | 1.79 | 63.18 | 13,980 | 13.3 |
| 5. | Zydus Lifesciences | 1,123.00 | 25.0 | 1,12,020 | 0.09 | 940 | -19.74 | 7,802 | 24.03 | 19.0 | 19.7 | 4.17 | 21.7 | 0.46 | 75.18 | 26,720 | 16.5 |
| 6. | Laurus Labs | 2,060.10 | 101.8 | 1,11,310 | 0.12 | 362 | 123.94 | 2,026 | 29.10 | 19.5 | 18.2 | 20.98 | 19.4 | 0.48 | 32.03 | 6,813 | 3.8 |
| 7. | Cipla | 1,325.10 | 31.8 | 1,07,051 | 0.98 | 786 | -39.18 | 7,119 | 2.33 | 14.9 | 11.8 | 3.11 | 17.5 | 0.02 | 31.13 | 28,163 | 7.2 |
| 8. | Dr. Reddy's Laboratories | 1,233.00 | 31.0 | 1,02,707 | 0.66 | 444 | -68.72 | 8,071 | -5.56 | 14.2 | 12.1 | 2.68 | 14.9 | 0.21 | 30.14 | 33,593 | 11.0 |
| 9. | Aurobindo Pharma | 1,666.90 | 26.0 | 95,910 | 0.00 | 1,033 | 14.29 | 9,106 | 8.65 | 13.5 | 9.9 | 2.56 | 15.6 | 0.21 | 54.79 | 33,385 | 10.7 |
| 10. | Mankind Pharma | 2,275.50 | 46.0 | 93,988 | 0.00 | 574 | 29.12 | 4,031 | 12.89 | 13.7 | 12.5 | 5.76 | 19.9 | 0.39 | 75.39 | 14,278 | 17.7 |
| Median: 57 Co. | 1,712.85 | 34.1 | 12,874 | 0.20 | 680 | 21.70 | 6,020 | 18.81 | 14.6 | 13.2 | 4.00 | 15.2 | 0.21 | 55.20 | 20,499 | 11.0 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
| ₹ Cr | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 35 | 34 | 36 | 36 | 43 |
| Operating Profit | 2 | 1 | 3 | 4 | 6 |
| Profit before tax | 2 | 1 | 3 | 5 | 6 |
| Net Profit | 0 | -0 | 1 | 1 | 2 |
| EPS in Rs | 0.74 | -0.20 | 1.59 | 1.85 | 2.55 |
Profit & Loss
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 101 | 104 | 120 | 140 | |
| Operating Profit | -1 | -3 | 4 | 10 | |
| Interest | 2 | 2 | 1 | 1 | |
| Depreciation | 4 | 5 | 5 | 5 | |
| Profit before tax | -1 | -4 | 13 | 11 | |
| Net Profit | -5 | -6 | 7 | 2 | |
| EPS in Rs | -7.90 | -10.62 | 12.70 | 3.99 |
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 |
| Reserves | 63 | 57 | 65 | 67 |
| 13 | 19 | 5 | 6 | |
| Long term borrowings | 4 | 9 | 2 | 1 |
| Short term borrowings | 7 | 9 | 1 | 4 |
| 70 | 79 | 72 | 88 | |
| Trade payables | 10 | 17 | 12 | 20 |
| Minority interest | 40 | 41 | 45 | 50 |
| Current liabilities | 28 | 37 | 21 | 34 |
| Total Liabilities | 152 | 161 | 148 | 167 |
| 84 | 86 | 74 | 73 | |
| Gross block | 128 | 134 | 117 | 121 |
| Accumulated depreciation | 44 | 48 | 44 | 48 |
| Goodwill & intangibles | 1 | 1 | 1 | 1 |
| CWIP | 0 | 0 | 1 | 4 |
| 68 | 75 | 73 | 89 | |
| Inventories | 31 | 34 | 34 | 45 |
| Trade receivables | 20 | 20 | 28 | 20 |
| Cash & equivalents | 1 | 0 | 0 | 0 |
| Current assets | 63 | 70 | 68 | 87 |
| Total Assets | 152 | 161 | 148 | 167 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| -9 | 1 | -4 | 14 | |
| Profit for the year | -5 | -6 | 7 | 2 |
| Working capital changes | -11 | 1 | -11 | 2 |
| Direct taxes paid | -2 | -2 | -2 | -3 |
| 1 | -7 | 20 | -15 | |
| Fixed assets purchased | -13 | -7 | -4 | -4 |
| Fixed assets sold | 0 | 0 | 19 | 0 |
| Investments purchased | -4 | |||
| Investments sold | 3 | 3 | ||
| 6 | 6 | -16 | 0 | |
| Proceeds from borrowings | 4 | 1 | ||
| Repayment of borrowings | -12 | -2 | -1 | -1 |
| Interest paid | -2 | -2 | -1 | -1 |
| Dividends paid | -1 | -1 | ||
| Net Cash Flow | -2 | -0 | -0 | -0 |
| Free Cash Flow | -22 | -6 | -8 | 11 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | -6.9% | -9.5% | 11.2% | 3.3% |
| ROCE | — | 1.0% | -1.6% | 11.6% | 9.0% |
| Operating margin | — | -0.7% | -3.1% | 3.5% | 7.5% |
| Net margin | — | -4.7% | -6.0% | 6.2% | 1.7% |
| Debt / equity | — | 0.19 | 0.31 | 0.07 | 0.08 |
| Current ratio | — | 2.30 | 1.88 | 3.22 | 2.56 |
| Debtor days | — | 72 | 70 | 85 | 52 |
| Inventory days | — | 185 | 188 | 168 | 195 |
| Days payable | — | 60 | 93 | 58 | 85 |
| Cash conversion cycle | — | 197 | 165 | 195 | 162 |
| Working capital days | — | 129 | 115 | 143 | 138 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
- Promoters & insiders 67.54%
- Institutions (FII, DII, funds) 0.00%
- Public & others 32.46%
Key dates
- Ex-dividend date
- 1 Jan 1970
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
From the company (NSE)
No recent announcements.
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Makers Laboratories Limited
What is the share price of Makers Laboratories Limited today?
What is the market cap of Makers Laboratories Limited?
What is the P/E ratio of Makers Laboratories Limited?
Is Makers Laboratories Limited a good investment?
How can I buy Makers Laboratories Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.